TY  - JOUR 
AU  - Pinto Merino, Álvaro
AU  - Labrador, Jorge
AU  - Zubiaur, Pablo
AU  - Alcaraz, Raquel
AU  - Herrero, María José
AU  - Montesinos, Pau
AU  - Abad Santos, Francisco
AU  - Saiz Rodríguez, Miriam
PY  - 2022
UR  - https://hdl.handle.net/10259/12198
AB  - Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or...
LA  - eng
PB  - MDPI
KW  - Acute myeloid leukemia
KW  - Pharmacogenetics
KW  - Cytarabine
KW  - Anthracyclines
KW  - FLT3 inhibitors
KW  - IDH inhibitors
KW  - CD33 inhibitors
KW  - Hypomethylating agents
KW  - BCL2 inhibitors
KW  - Leucemia mieloide aguda
KW  - Acute myeloid leukemia
TI  - Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
DO  - 10.3390/PHARMACEUTICS14030559
T2  - Pharmaceutics
VL  - 14
M2  - 559
ER  -